Page 1 of Clinical Trials for Bioavailability Pharmacokinetic Formulation, 139 Total Matches

Show/Hide Clinical Trials Which are Not Seeking New Volunteers

1
Completed
Bioavailability of 3 Sildenafil Oral Disintegrating Tablet Formulations Compared to the Standard Oral Tablet
Last Updated: October 5, 2009
Condition(s): Healthy Volunteers
2
Completed
A Pharmacokinetic Study of the Relative Bioavailability of Paliperidone ER Formulations With Different Release Profiles and a Comparison to Paliperidone IR
Last Updated: May 17, 2011
Condition(s): Schizophrenia
3
Completed
A Phase I Study of the Pharmacokinetic Variability and Relative Bioavailability of the Phase 3 and Common Blend Formulations of Eliglustat in Healthy Adult Subjects
Last Updated: April 6, 2012
Condition(s): Healthy Volunteer
4
Not yet recruiting
Comparative Bioavailability Study of an Immediate Release and Controlled Release Oral Formulations of Huperzine A
Last Updated: June 2, 2010
Condition(s): Healthy; Bioavailability
5
Completed
A Pilot Open-Label Crossover Bioavailability Study of Celecoxib in Healthy Volunteers
Last Updated: March 1, 2010
Condition(s): Healthy Volunteers
6
Completed
A Single Oral Dose Study of ASP015K in Healthy Volunteers Assessing the Relative Bioavailability Across Three Tablet Strengths From a New Formulation of ASP015K
Last Updated: December 2, 2011
Condition(s): Bioavailability of ASP015K; Pharmacokinetics of ASP015K; Healthy Subjects
7
Completed
Exploratory Pharmacokinetic and Bioavailability Study of 2 Capsule Formulations of Torezolid Phosphate
Last Updated: October 12, 2011
Condition(s): Healthy
8
Recruiting
Comparative Bioavailability - Gender Effect - Single and Multiple Ascending Dose Safety and Pharmacokinetic Study of GFT505
Last Updated: January 3, 2012
Condition(s): Type 2 Diabetes; Diabetes Mellitus, Type 2; Metabolic Diseases; Cardiovascular Diseases; Obese; Dyslipidemia
9
Completed
Bioavailability of ABT-333 Tablet Versus First in Human (FIH) Capsule Formulation and Safety, Tolerability and PK Study of Single Doses of ABT-333 in Healthy Volunteers
Last Updated: October 12, 2010
Condition(s): HCV Infection
10
Completed
A Single Oral Dose Study to Compare the Bioavailability Between Two Different Tablet Formulations and Assess if There is a Food Effect With the New Formulation
Last Updated: December 1, 2011
Condition(s): Pharmacokinetics of ASP015K; Bioavailability of ASP015K; Healthy Subjects
11
Completed
Influence of Food-intake on Desmopressin Oral Tablets and MELT-formulation
Last Updated: May 25, 2011
Condition(s): Enuresis; Polyuria
12
Completed
To Compare Relative Bioavailability of Two Clinical Formulations of Linifanib.
Last Updated: March 21, 2012
Condition(s): Advanced Solid Tumors
13
Completed
Relative Bioavailability of Phase II and Phase III Formulations of AZD0530
Last Updated: June 17, 2009
Condition(s): Healthy
14
Completed
Pharmacokinetics of 3 Formulations of Ibuprofen Suppositories
Last Updated: October 4, 2011
Condition(s): Healthy
15
Completed
A Pharmacokinetic and Relative Bioavailability Study With Rabeprazole Sodium in Healthy Adult Volunteers
Last Updated: April 8, 2010
Condition(s): Gastroesophageal Reflux
16
Active, not recruiting
Pharmacokinetic Study for PCA Derivate Formulations
Last Updated: September 28, 2008
Condition(s): Healthy
17
Completed
An Open-label Single Dose Randomized, Parallel Group Study Followed by Single-blind Repeat Dosing, to Compare the Relative Bioavailability of GSK2212836.
Last Updated: January 22, 2011
Condition(s): Hypertriglyceridemia; Cardiovascular Disease
18
Completed
Relative Bioavailability and Food Effect Study for GSK163090 in Healthy Male and Female Volunteers
Last Updated: October 13, 2010
Condition(s): Depression; Anxiety Disorder
19
Completed
Assess the Effect of Food on Avanafil Pharmacokinetic (PK), to Compare 2 Oral Formulations of Avanafil,and Investigate Dose Proportionality in Healthy Male Subjects
Last Updated: January 5, 2011
Condition(s): Healthy
20
Completed
A Study to Assess the Relative Bioavailability of Different Formulations of GSK2018682, a Sphingosine-1-phosphate Receptor Subtype 1 Agonist, in Healthy Volunteers.
Last Updated: February 2, 2012
Condition(s): Multiple Sclerosis, Relapsing-Remitting

Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.

The URL of this page is: http://clinicaltrialsfeeds.org/clinical-trials/results/?term=Bioavailability+Pharmacokinetic+Formulation

Page 1 of Clinical Trials for Bioavailability Pharmacokinetic Formulation, 139 Total Matches

Get the Latest Results via Email or RSS

Subscribe via Web Newsreaders

Browse

Clinical Trials Background

About